Tekmira Pharmaceuticals, the Vancouver, BC-based developer of RNA interference drugs, said today it has formed a partnership with New York-based Pfizer (NYSE: [[ticker:PFE]]) to use its lipid-nanoparticle technology as a delivery vehicle for Pfizer’s RNAi drug candidates. Tekmira will make the drug formulations, while Pfizer will run the animal tests. This marks the latest significant partnership for Tekmira to use its RNAi technology, counting deals with Cambridge, MA-based Alnylam Pharmaceuticals and Roche. Terms of the Pfizer partnership weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
